Source: Eur Respir J 2003 Oct 01;22(4):592-595



Rating:

Share or cite this content

Citations should be made in the following way:
Krane M., Griese M.. Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis. Eur Respir J 2003 Oct 01;22(4):592-595

Member's Comments

No comment yet.

Related content which might interest you: Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020 Year: 2020 Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2008; 31: 36-42 Year: 2008 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 156 Year: 2001 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Annual Congress 2009 - Update on eosinophilic lung diseases Year: 2009 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 1052-1053 Year: 2001 Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease? Source: Eur Respir Rev 2010 19: 261-263 Year: 2010 Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis Source: Eur Respir Rev 2010 19: 349-351 Year: 2010 Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Elevated CEA levels in sera in patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2011 - Biomarkers of allergic inflammation Year: 2011 Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis Source: Eur Respir J 2014; 43: 1487-1500 Year: 2014 Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2016; 47: 177-185 Year: 2016 Airway remodelling easily develops in patients with allergic bronchopulmonary aspergillosis Source: Annual Congress 2009 - Airways remodelling Year: 2009 Vitamin D deficiency in asthma patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Follow-up of patients with allergic bronchopulmonary aspergillosis (ABPA) - side effects of long-term therapy Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Bronchopulmonary aspergillosis Source: Respipedia Article Year: 2017